146 related articles for article (PubMed ID: 9211892)
1. Carboxymethylethanolamine, a biomarker of phospholipid modification during the maillard reaction in vivo.
Requena JR; Ahmed MU; Fountain CW; Degenhardt TP; Reddy S; Perez C; Lyons TJ; Jenkins AJ; Baynes JW; Thorpe SR
J Biol Chem; 1997 Jul; 272(28):17473-9. PubMed ID: 9211892
[TBL] [Abstract][Full Text] [Related]
2. Quantification of N-(glucitol)ethanolamine and N-(carboxymethyl)serine: two products of nonenzymatic modification of aminophospholipids formed in vivo.
Fountain WC; Requena JR; Jenkins AJ; Lyons TJ; Smyth B; Baynes JW; Thorpe SR
Anal Biochem; 1999 Jul; 272(1):48-55. PubMed ID: 10405292
[TBL] [Abstract][Full Text] [Related]
3. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo.
Takeuchi M; Makita Z; Bucala R; Suzuki T; Koike T; Kameda Y
Mol Med; 2000 Feb; 6(2):114-25. PubMed ID: 10859028
[TBL] [Abstract][Full Text] [Related]
4. Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry.
Teerlink T; Barto R; Ten Brink HJ; Schalkwijk CG
Clin Chem; 2004 Jul; 50(7):1222-8. PubMed ID: 15131022
[TBL] [Abstract][Full Text] [Related]
5. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA.
Galler A; Müller G; Schinzel R; Kratzsch J; Kiess W; Münch G
Diabetes Care; 2003 Sep; 26(9):2609-15. PubMed ID: 12941727
[TBL] [Abstract][Full Text] [Related]
6. Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction.
Shibayama R; Araki N; Nagai R; Horiuchi S
Diabetes; 1999 Sep; 48(9):1842-9. PubMed ID: 10480617
[TBL] [Abstract][Full Text] [Related]
7. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.
Reddy S; Bichler J; Wells-Knecht KJ; Thorpe SR; Baynes JW
Biochemistry; 1995 Aug; 34(34):10872-8. PubMed ID: 7662668
[TBL] [Abstract][Full Text] [Related]
8. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations.
Hammes HP; Brownlee M; Lin J; Schleicher E; Bretzel RG
Diabetologia; 1999 May; 42(5):603-7. PubMed ID: 10333054
[TBL] [Abstract][Full Text] [Related]
9. Antibodies against advanced glycation end product Nepsilon-(carboxymethyl)lysine in healthy controls and diabetic patients.
Vay D; Vidali M; Allochis G; Cusaro C; Rolla R; Mottaran E; Bellomo G; Albano E
Diabetologia; 2000 Nov; 43(11):1385-8. PubMed ID: 11126407
[TBL] [Abstract][Full Text] [Related]
10. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions.
Fu MX; Requena JR; Jenkins AJ; Lyons TJ; Baynes JW; Thorpe SR
J Biol Chem; 1996 Apr; 271(17):9982-6. PubMed ID: 8626637
[TBL] [Abstract][Full Text] [Related]
11. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients.
Takeuchi M; Makita Z; Yanagisawa K; Kameda Y; Koike T
Mol Med; 1999 Jun; 5(6):393-405. PubMed ID: 10415164
[TBL] [Abstract][Full Text] [Related]
12. Dietary intake of advanced glycation endproducts is associated with higher levels of advanced glycation endproducts in plasma and urine: The CODAM study.
Scheijen JLJM; Hanssen NMJ; van Greevenbroek MM; Van der Kallen CJ; Feskens EJM; Stehouwer CDA; Schalkwijk CG
Clin Nutr; 2018 Jun; 37(3):919-925. PubMed ID: 29381139
[TBL] [Abstract][Full Text] [Related]
13. Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions.
Requena JR; Fu MX; Ahmed MU; Jenkins AJ; Lyons TJ; Thorpe SR
Nephrol Dial Transplant; 1996; 11 Suppl 5():48-53. PubMed ID: 9044307
[TBL] [Abstract][Full Text] [Related]
14. N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function.
Wagner Z; Wittmann I; Mazák I; Schinzel R; Heidland A; Kientsch-Engel R; Nagy J
Am J Kidney Dis; 2001 Oct; 38(4):785-91. PubMed ID: 11576882
[TBL] [Abstract][Full Text] [Related]
15. Maillard reactions by alpha-oxoaldehydes: detection of glyoxal-modified proteins.
Sady C; Jiang CL; Chellan P; Madhun Z; Duve Y; Glomb MA; Nagaraj RH
Biochim Biophys Acta; 2000 Sep; 1481(2):255-64. PubMed ID: 11018716
[TBL] [Abstract][Full Text] [Related]
16. Formation of N-(hexanoyl)ethanolamine, a novel phosphatidylethanolamine adduct, during the oxidation of erythrocyte membrane and low-density lipoprotein.
Tsuji K; Kawai Y; Kato Y; Osawa T
Biofactors; 2004; 21(1-4):263-6. PubMed ID: 15630208
[TBL] [Abstract][Full Text] [Related]
17. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes.
Berg TJ; Clausen JT; Torjesen PA; Dahl-Jørgensen K; Bangstad HJ; Hanssen KF
Diabetes Care; 1998 Nov; 21(11):1997-2002. PubMed ID: 9802757
[TBL] [Abstract][Full Text] [Related]
18. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia?
Miyata T; Fu MX; Kurokawa K; van Ypersele de Strihou C; Thorpe SR; Baynes JW
Kidney Int; 1998 Oct; 54(4):1290-5. PubMed ID: 9767546
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of Maillard reaction products in skin collagen in diabetes and aging.
Dyer DG; Dunn JA; Thorpe SR; Bailie KE; Lyons TJ; McCance DR; Baynes JW
J Clin Invest; 1993 Jun; 91(6):2463-9. PubMed ID: 8514858
[TBL] [Abstract][Full Text] [Related]
20. Technical note. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl)lysine is increased in uremia.
Degenhardt TP; Grass L; Reddy S; Thorpe SR; Diamandis EP; Baynes JW
Kidney Int; 1997 Oct; 52(4):1064-7. PubMed ID: 9328946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
